2024-11-01 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, reagents, and consumables for research, diagnostics, and pharmaceutical industries.

**1. Performance Comparison:**

* **Cumulative Return:** TMO: 212.16%, VOO (S&P 500): 131.38%
* **Outperformance:** TMO has significantly outperformed the S&P 500, with a cumulative return difference of 80.78%. This puts TMO in the 37.81% percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movements:**

* **Closing Price:** $546.32
* **5-day Moving Average:** $550.33
* **20-day Moving Average:** $582.35
* **60-day Moving Average:** $600.82
* **Analysis:** TMO's current price is below its 5-day, 20-day, and 60-day moving averages, indicating a possible short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 22.0 - This suggests the stock is oversold, indicating potential for a rebound.
* **PPO:** -0.82 - This indicates a strong downward trend, aligning with the recent price movement.
* **Delta_Previous_Relative_Divergence:** -14.08 - This points to a short-term downtrend. 
* **Expected Return:** 46.73% - This represents the expected long-term (2 years+) outperformance over the S&P 500.

**4. Recent Earnings and Outlook:**

| Date         | EPS | Revenue       |
|--------------|-----|---------------|
| 2024-08-02  | 4.05 | $10.54 B      |
| 2024-05-03  | 3.47 | $10.35 B      |
| 2023-11-03  | 4.44 | $10.57 B      |
| 2023-08-04  | 3.53 | $10.69 B      |
| 2024-08-02  | 3.53 | $10.69 B      |

**Analysis:**

* **Recent Earnings:** The latest earnings for Q2 2024 reported EPS of $4.05, exceeding analyst expectations. Revenue also came in strong at $10.54B.
* **Trend:** Revenue has been consistently strong, demonstrating the company's stable market position. However, EPS has been fluctuating, indicating potential challenges or opportunities.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2024-06-30  | $10.54B | 41.24%        |
| 2024-03-31  | $10.35B | 40.65%        |
| 2023-12-31  | $10.89B | 40.35%        |
| 2023-09-30  | $10.57B | 40.82%        |
| 2023-06-30  | $10.69B | 39.78%        |

**Analysis:**

* **Stable Profitability:** The profit margin has remained relatively stable, indicating a consistent ability to generate profits.
* **Strong Revenue Growth:** Revenue has consistently grown over the past year, showcasing the company's strong market position and demand for its products.

**2) Capital and Profitability:**

| Quarter      | Equity  | ROE   |
|--------------|---------|-------|
| 2024-06-30  | $47.43B | 3.26% |
| 2024-03-31  | $45.52B | 2.92% |
| 2023-12-31  | $46.73B | 3.49% |
| 2023-09-30  | $45.33B | 3.78% |
| 2023-06-30  | $43.75B | 3.11% |

**Analysis:**

* **Steady Growth:** Equity and ROE have shown steady growth over the past year, indicating a healthy financial position and efficient capital utilization.

**6. News and Recent Events:**

* **Earnings Release:** The recent Q2 2024 earnings release on August 2nd, 2024, showed strong results, exceeding analyst expectations.
* **Recent Market Outlook:**  Many analysts believe TMO is a solid long-term investment, given its strong financial performance and its position in a growing market.
* **Analyst Opinions:** Finbold reported that the majority of analysts have a "Buy" rating on TMO, with a consensus target price of $600. 
* **Performance Highlights:** TMO has been a consistent performer in the past, delivering steady growth and strong returns for investors.

**7. Overall Analysis:**

* TMO has demonstrated strong performance, outperforming the S&P 500 significantly. 
* Technical indicators point to a possible short-term downtrend, but the oversold RSI suggests potential for a rebound.
* The company's strong financial position, consistent revenue growth, and strong earnings performance make it an attractive long-term investment.
* Analysts remain positive on TMO, with a majority recommending a "Buy" rating.

**8. Conclusion:**

Overall, Thermo Fisher Scientific Inc. (TMO) appears to be a solid long-term investment, with a strong track record of financial performance, a leading position in the scientific instrumentation market, and a favorable outlook. While the recent price movement suggests a short-term downtrend, the company's strong fundamentals and analyst optimism indicate potential for growth and outperformance in the long run.
